|Geron Appoints Susan Molineaux and Daniel Bradbury to Board of Directors|
MENLO PARK, Calif., September 28, 2012 - Geron Corporation (Nasdaq: GERN) today announced the appointment of Susan M. Molineaux, Ph.D., and Daniel M. Bradbury to its board of directors. Dr. Molineaux is joining the board's nominating and corporate governance committee and Mr. Bradbury is joining the board's audit committee.
"In making these two appointments, we are adding important skill sets to our board of directors," said John A. Scarlett, M.D., Geron's President and Chief Executive Officer. "Dr. Molineaux has substantial experience as an oncology drug developer, with an emphasis on translating cutting edge biology into clinically relevant drugs. Mr. Bradbury brings extensive leadership experience from a highly successful commercial biopharmaceutical company. We welcome Susan and Dan to our board of directors and look forward to their contribution as we drive our oncology development programs forward."
Susan M. Molineaux
Dr. Molineaux has more than 20 years of biotechnology industry experience. She currently serves as Chief Executive Officer and President of Calithera Biosciences, Inc., which she co-founded in June 2010. Prior to Calithera, Dr. Molineaux co-founded Proteolix, Inc. where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009, and as President and Chief Executive Officer from January 2006 until February 2009. Dr. Molineaux was responsible for leading the development of Proteolix's second generation proteasome inhibitor, carfilzomib (now marketed as Kryprolis), for the treatment of multiple myeloma, from discovery through completion of clinical trials for accelerated approval, until the company's acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc. She served as Vice President of Biology at Praelux, Inc. from 1999 to 2000, and from 1994 through 1999, as Vice President of Drug Development at Praecis Pharmaceuticals, Inc. From 1989 until 1994, she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux holds a B.S. degree in Biology from Smith College and a Ph.D. degree in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University. She currently serves as the Co-Vice Chair of Bay Bio, Northern California's Life Science Association, and as a member of the board of directors of We Teach Science, a San Francisco Bay Area mentoring program for students in math and science.
Daniel M. Bradbury
Mr. Bradbury has nearly 30 years of pharmaceutical and biotechnology industry experience. He serves as a member of the boards of directors of Illumina, Inc. and Castle Biosciences and the board of trustees for the Keck Graduate Institute. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., from March 2007 until its acquisition by Bristol-Myers Squibb Company for approximately $7 billion in August 2012. Mr. Bradbury served as Amylin's President from June 2006 until March 2007, as Chief Operating Officer from June 2003 until June 2006, as Executive Vice President from June 2000 until June 2003 and in other positions in corporate development and marketing from 1994 until 2000. In addition, Mr. Bradbury served as a member of the board of directors of Amylin from June 2006 until August 2012. Prior to joining Amylin, he spent ten years at SmithKline Beecham Pharmaceuticals, holding a number of sales and marketing positions. Mr. Bradbury serves on the University of California San Diego, Rady School of Management's Advisory Council, RAND Health Board of Advisors and University of Miami's Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Geron is a biopharmaceutical company developing first-in-class therapies for cancer. The company has two lead product candidates in clinical development, imetelstat and GRN1005. Imetelstat is a telomerase inhibitor that is being evaluated in three ongoing Phase 2 clinical trials: advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma. GRN1005 is a peptide-drug conjugate that is designed to transport a proven anti-cancer drug, paclitaxel, across the blood-brain barrier by targeting low-density lipoprotein receptor-related proteins (LRPs), specifically LRP-1. GRN1005 is being evaluated in two Phase 2 clinical trials: brain metastases arising from breast cancer and brain metastases arising from non-small cell lung cancer. For more information about Geron, visit www.geron.com.
Anna Krassowska, Ph.D.
|Print Page | E-mail Page | RSS Feeds | E-mail Alerts|